| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $50,164,038 | 43 | 100 |
| Krishnan Mahesh | director | 0 | $0 | 1 | $547,800 | $-547,800 |
| Connaughton Bernadette | director | 0 | $0 | 7 | $839,366 | $-839,366 |
| Caudill Cortney | SVP, CHIEF OPERATING OFFICER | 0 | $0 | 2 | $1.96M | $-1.96M |
| Posard Matthew L. | director | 0 | $0 | 2 | $2.61M | $-2.61M |
| Torley Helen | PRESIDENT AND CEO | 0 | $0 | 31 | $44.21M | $-44.21M |
Halozyme Therapeutics, Inc. is a biopharmaceutical company headquartered in San Diego, California, with operations spanning the United States, Switzerland, Ireland, Belgium, Japan, and other international markets. At its core is the proprietary ENHANZE drug delivery platform, which utilizes a patented recombinant human hyaluronidase enzyme (rHuPH20). This innovative technology significantly enhances the subcutaneous (under-the-skin) administration of a diverse range of injectable medicines. This includes complex biologics such as monoclonal …
Over the last 12 months, insiders at Halozyme Therapeutics, Inc. have bought $0 and sold $50.16M worth of Halozyme Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Halozyme Therapeutics, Inc. have bought $0 and sold $23.54M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 52,629 shares for transaction amount of $748,697 was made by Kelley Kenneth J (director) on 2020‑03‑19.
| 2026-10-08 | Sale | Torley Helen | PRESIDENT AND CEO | 20,000 0.0168% | $109.40 | $2.19M | +13.52% | |
| 2026-10-07 | Sale | Torley Helen | PRESIDENT AND CEO | 20,000 0.017% | $111.55 | $2.23M | +12.41% | |
| 2026-10-06 | Sale | Torley Helen | PRESIDENT AND CEO | 20,000 0.0168% | $109.58 | $2.19M | +13.43% | |
| 2026-10-01 | Sale | Posard Matthew L. | director | 5,230 0.0045% | $108.54 | $567,661 | +14.55% | |
| 2026-09-16 | Sale | Posard Matthew L. | director | 18,996 0.0159% | $107.74 | $2.05M | +5.60% | |
| 2026-09-11 | Sale | Torley Helen | PRESIDENT AND CEO | 20,000 0.0169% | $107.24 | $2.14M | +5.31% | |
| 2026-09-10 | Sale | Torley Helen | PRESIDENT AND CEO | 20,000 0.0169% | $107.17 | $2.14M | +5.30% | |
| 2026-09-09 | Sale | Torley Helen | PRESIDENT AND CEO | 20,000 0.0169% | $107.43 | $2.15M | +4.71% | |
| 2026-08-19 | Sale | Torley Helen | PRESIDENT AND CEO | 16,800 0.0141% | $106.85 | $1.8M | +2.60% | |
| 2026-08-19 | Sale | Torley Helen | PRESIDENT AND CEO | 20,000 0.0168% | $107.00 | $2.14M | +2.60% | |
| 2026-08-18 | Sale | Torley Helen | PRESIDENT AND CEO | 20,000 0.0167% | $104.18 | $2.08M | +5.26% | |
| 2026-08-17 | Sale | Torley Helen | PRESIDENT AND CEO | 20,000 0.017% | $102.60 | $2.05M | +7.18% | |
| 2026-08-10 | Sale | Connaughton Bernadette | director | 1,626 0.0014% | $102.80 | $167,153 | +7.05% | |
| 2026-07-08 | Sale | Torley Helen | PRESIDENT AND CEO | 1,923 0.0016% | $79.77 | $153,391 | +34.30% | |
| 2026-07-01 | Sale | Connaughton Bernadette | director | 1,625 0.0014% | $76.71 | $124,651 | +39.75% | |
| 2026-06-29 | Sale | Krishnan Mahesh | director | 7,304 0.006% | $75.00 | $547,800 | +39.14% | |
| 2026-06-03 | Sale | Torley Helen | PRESIDENT AND CEO | 3,900 0.0032% | $68.09 | $265,532 | +51.44% | |
| 2026-06-03 | Sale | Torley Helen | PRESIDENT AND CEO | 10,000 0.0088% | $69.07 | $690,653 | +51.44% | |
| 2026-06-02 | Sale | Torley Helen | PRESIDENT AND CEO | 20,000 0.0169% | $66.39 | $1.33M | +58.95% | |
| 2026-06-01 | Sale | Torley Helen | PRESIDENT AND CEO | 20,000 0.0167% | $67.58 | $1.35M | +54.27% |
| Torley Helen | PRESIDENT AND CEO | 767780 0.6765% | $98.75M | 1 | 91 | +68.25% |
| Frost Gregory Ian | CEO, President | 3555331 3.1325% | $457.29M | 4 | 16 | +20.07% |
| KIRK RANDAL J | 10 percent owner | 1897610 1.6719% | $244.07M | 56 | 18 | +103.3% |
| Lim Jonathan E | President, CEO | 680000 0.5991% | $87.46M | 1 | 8 | +18.01% |
| RAMSAY DAVID A | VP and Chief Financial Officer | 323492 0.285% | $41.61M | 7 | 3 | +24.44% |
| FALBERG KATHRYN E | director | 280000 0.2467% | $36.01M | 3 | 0 | +46.53% |
| Engler Robert | director | 273176 0.2407% | $35.14M | 5 | 3 | +18.07% |
| Kelley Kenneth J | director | 179833 0.1584% | $23.13M | 3 | 22 | +50.56% |
| Shaffer James P | VP & Chief Commercial Officer | 26300 0.0232% | $3.38M | 1 | 0 | +34.45% |
| LITTLE ROBERT J | VP, Chief Commercial Officer | 13000 0.0115% | $1.67M | 2 | 0 | <0.0001% |
| Stelzer Laurie | Chief Financial Officer | 10000 0.0088% | $1.29M | 1 | 0 | <0.0001% |
| GUSTAFSON KURT A | Vice President and CFO | 8000 0.007% | $1.03M | 1 | 0 | |
| Kennard Don A | Vice President, Regulatory Aff | 3000 0.0026% | $385,860.00 | 1 | 0 | +31.79% |
$961,890,236 | 276 | 22.46% | $23.97B | |
$273,531,368 | 93 | 38.24% | $9.16B | |
$2,765,836 | 72 | 20.00% | $10.77B | |
Halozyme Therapeutics, Inc. (HALO) | $108,876,545 | 67 | 72.81% | $14.6B |
$11,991,408 | 51 | 18.36% | $22.91B |
| Increased Positions | 332 | +48.12% | 18M | +14.8% |
| Decreased Positions | 309 | -44.78% | 15M | -12.14% |
| New Positions | 106 | New | 5M | New |
| Sold Out Positions | 79 | Sold Out | 4M | Sold Out |
| Total Postitions | 713 | +3.33% | 124M | +2.66% |
| Blackrock, Inc. | $904,201.00 | 10.9% | 12.86M | -339,833 | -2.57% | 2025-09-30 |
| Vanguard Group Inc | $817,690.00 | 9.86% | 11.63M | -615,816 | -5.03% | 2025-09-30 |
| State Street Corp | $352,900.00 | 4.25% | 5.02M | -915,838 | -15.43% | 2025-09-30 |
| Arrowstreet Capital, Limited Partnership | $231,367.00 | 2.79% | 3.29M | +749,484 | +29.49% | 2025-09-30 |
| Invesco Ltd. | $228,210.00 | 2.75% | 3.25M | -220,119 | -6.35% | 2025-09-30 |
| Ubs Group Ag | $207,116.00 | 2.5% | 2.95M | +1M | +93.24% | 2025-09-30 |
| Snyder Capital Management L P | $192,217.00 | 2.32% | 2.73M | -663,853 | -19.54% | 2025-09-30 |
| D. E. Shaw & Co., Inc. | $186,348.00 | 2.25% | 2.65M | +2M | +160.15% | 2025-09-30 |
| Geode Capital Management, Llc | $170,943.00 | 2.06% | 2.43M | -1,230 | -0.05% | 2025-09-30 |
| Dimensional Fund Advisors Lp | $146,134.00 | 1.76% | 2.08M | +63,699 | +3.16% | 2025-09-30 |